Chisholm, Alison
Price, David B http://orcid.org/0000-0002-9728-9992
Pinnock, Hilary
Lee, Tan Tze
Roa, Camilo
Cho, Sang-Heon
David-Wang, Aileen
Wong, Gary
van der Molen, Thys
Ryan, Dermot http://orcid.org/0000-0002-4115-7376
Castillo-Carandang, Nina
Yong, Yee Vern
,
Article History
Received: 27 November 2015
Revised: 10 August 2016
Accepted: 25 September 2016
First Online: 5 January 2017
Change Date: 16 January 2018
Change Type: Correction
Change Details: The Figure files initially published online in the PDF version of this paper were corrupted and replaced on 16 January 2018.
Competing interests
: ADW has received honoraria from Mundipharma for my participation in the REALISE Asia Working Group meetings and discussions, is a member of Mundipharma’s Asia-Pacific Advisory Board and has received speaker fees from Mundipharma, but has no competing interests to disclose in relation to this paper. NCC has received payments for lectures/speaking from Mundipharma Asia Pte and payment for travel/accommodations/meeting expenses from Mundipharma Asia Pte. TvdM has been a member of advisory boards for Almiral, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis and Teva; TvdM offered consultancy to Almiral, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Mundipharma, Novartis, Nycomed, Certe and Teva; TvdM received grants from the University of Groningen, the Lung Foundation Netherlands, Stichting bestrijding Astma, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed; TvdM received payments for lectures/speaking from Almiral, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Merck, Mundipharma,and Teva; TvdM received payment for the development of educational materials from Mundipharma, Teva; TvdM received payment for travel/accommodations/meeting expenses from Boehringer Ingelheim, Astrazeneca, Novartis, Mundipharma and Teva and has the following patents (planned, pending or issued): CCQ copyrights ICQ copyrights BHQ copyrights. DBP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from UK National Health Service, British Lung Foundation, Aerocrine, AKL Ltd, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Zentiva, and Theravance; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Novartis and Mundipharma; payment for travel/accommodation/meeting expenses from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals, and AstraZeneca; funding for patient enrolment or completion of research from Chiesi, Teva Pharmaceuticals, Zentiva, and Novartis; stock/stock options from AKL Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore; and is peer reviewer for grant committees of the Medical Research Council, Efficacy and Mechanism Evaluation programme, and HTA; and received unrestricted funding for investigator-initiated studies from Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, and Zentiva. The remaining authors declare no conflict of interest.